Quantinno Capital Management LP Has $2.15 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)

Quantinno Capital Management LP trimmed its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 36.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 149,833 shares of the company's stock after selling 85,193 shares during the quarter. Quantinno Capital Management LP owned about 0.12% of 10x Genomics worth $2,152,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of TXG. Signaturefd LLC boosted its position in shares of 10x Genomics by 424.6% during the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after purchasing an additional 1,452 shares in the last quarter. Blue Trust Inc. raised its stake in 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after buying an additional 1,299 shares during the period. Sound Income Strategies LLC boosted its holdings in 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after acquiring an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in 10x Genomics in the fourth quarter worth approximately $52,000. Finally, SRS Capital Advisors Inc. grew its stake in 10x Genomics by 817.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock valued at $70,000 after acquiring an additional 4,324 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Trading Up 1.7%

Shares of 10x Genomics stock opened at $9.08 on Wednesday. The business's fifty day simple moving average is $8.72 and its 200 day simple moving average is $12.23. 10x Genomics, Inc. has a 12 month low of $6.78 and a 12 month high of $24.85. The firm has a market capitalization of $1.11 billion, a P/E ratio of -5.97 and a beta of 1.94.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. The company had revenue of $154.88 million for the quarter, compared to analysts' expectations of $131.91 million. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. The business's revenue for the quarter was down 2.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.50) EPS. Analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TXG has been the topic of a number of research reports. The Goldman Sachs Group lowered their target price on 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a research report on Monday, May 12th. Leerink Partnrs downgraded shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 13th. Stifel Nicolaus dropped their price objective on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Morgan Stanley decreased their target price on shares of 10x Genomics from $26.00 to $18.00 and set an "overweight" rating for the company in a research report on Monday. Finally, Citigroup lowered their target price on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $15.81.

Insiders Place Their Bets

In other 10x Genomics news, CEO Serge Saxonov sold 5,092 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the transaction, the chief executive officer now directly owns 879,482 shares of the company's stock, valued at approximately $9,735,865.74. This represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the sale, the insider now directly owns 335,324 shares of the company's stock, valued at $3,712,036.68. This represents a 1.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 9.39% of the company's stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.